Rob Baker
Chief Executive Officer at CAMBRIDGE COGNITION HOLDINGS PLC
Replay available
Interim Results for the six months to 30 June 2026 hosted by Cambridge Cognition Holdings (LSE:COG) on Investor Meet Company. Replay available.

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Good afternoon, ladies and gentlemen. Welcome to the Cambridge Cognition Holdings PLC interim results investor presentation. Questions are encouraged. They can be submitted at any time via the q and a tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and will publish your responses where it's appropriate to do so on the Investor Meet company platform. Before we begin, we would just like to submit the following poll. And if you give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to CEO, Rob Baker. Rob, good afternoon, sir. Good afternoon, and thank you all for joining us today to go through the first half results of 2026 and interim results to date. Say, I'm Rob Baker, the chief executive officer, and with me is Ronald Openshaw. Hi. Good afternoon. Ronald Openshaw.
0:52 And we're gonna just walk through today just a recap of the results from the announcements that we shared earlier today, an opportunity to look at the order book and how that runs out, and also importantly about how our strategy and our platform strategy supports the flywheel on the growth objectives of the organization. So I'd like to start with reflecting on the highlights of the first half of twenty twenty six. Importantly, the first half revenue is up 16% compared to the prior period in 2025 at 5,000,000. We have reduced the loss and EBITDA loss from 0.4 in the prior period in the first half of twenty twenty five to 300,000 loss in the first half of twenty twenty six. The underpinned order book and revenue that sits there is at 10,000,000 at this point in comparative period of the revenue for full year 2025 of 9,400,000.
1:47 So showing that year on year growth. And we sat at the end of the period with a 400,000 net cash position. But importantly across all of the progress we've made in the first half is we have returned to positive trading, to strengthened liquidity, and for that investment and positioning for growth. Reflecting on that positive trading, we can see that also we've seen our first revenues from the health care and consumer wellness part of the organization. And whilst we reflect on that underpin revenue, we recognize that we've also seen about 700,000 of what was 2026 revenue move into 2027. And subsequently, because of the nature of the clinical trials, it doesn't mean that adds on, but actually the whole clinical trial moves to the right as such. So from that perspective, we're also seeing that revenue from 2027 move to '28 and '28 to '29 depending on the length of those studies. Now importantly for us, that reflects two studies that have moved out, and this is a reflection of the customer revising their timelines versus anything substantial within the delivery program of what Cambridge cognition delivers, but reflects the nature of how clinical trials can move in terms of their start date and their first patient, first visit. So from that perspective, we feel confident that these are obviously revenues that haven't been lost. These are revenues that have subsequently just moved out, and we would recognize them in future periods.
3:14 As you say, the new sales order for the first half was at 6,000,000, but importantly, there was a 1,000,000 signature deal that was closed in the first three days of July. And so actually, when we look at that in terms of reflecting period on period, we'd executed on their side, but the customer is still executing on on their side. That means actually that when we look at the year on year growth, we see that continued momentum within sales. When we look at EBITDA loss, it's improved to 300,000 from that 400,000 loss from prior period. And also as we reflect and look at the things like pre r and d EBITDA, it's improved to a positive 670,000 from a previous period in the h one twenty twenty five of 560,000.
3:59 And I'm sure, Ron, as we go into the balance sheet, we'll reflect a little bit more about why we've distinguished those differences within both EBITDA and EBITDA pre r and d. We've seen positive operational cash flow in the first half of the year up to 267 from a prior comparative period of a loss of 251. This really means that the underpinning, and as we look at the organization as a whole and the health of the organization, actually being cash generative within that piece is a good signal and a leading indicator for the strength of the underlying business. Again, reflecting this is majority still our traditional academic and clinical part of the organization. We have reduced those borrowings down and actually as post period end, we have fully repaid and the company is now debt free from those borrowings.
4:46 And as we step forward, we've obviously completed that raise earlier this year at 2,600,000 placing before finance costs and those allocations on three investment programs, which we're gonna take an opportunity to reflect on their progress to date, but also positions us for investing for growth in the future. Maybe hand over to you, Ron, and I'll talk a little bit more about the the financing balance sheet. Super. Thank you. So as you can see from the income statement, we add an extra line here, which is sales orders. It's not the revenue generated. It's the orders that we've taken in. Rob, you mentioned a moment ago that a million pounds worth of sales orders was received in the, first three days or on third day of July. We weren't wonderfully thrilled that it wasn't in the final days of June. So as we look at it within the management team, we we recognize that actually what we did in the first half is 7,000,000 of selling, not 6,000,000, and that's comparative to the previous year. When we then run through the rest of the profit loss account, revenue's up 5,000,000 versus 4.3.
5:51 Gross profit is up 3.8 versus 3.1, and it's not just the extra revenue that's given us. We've seen the three percentage point improvement in the gross margin from 72 to 75%. Operating expenses up to 4.4 from four point o, and we took a decision. We took a deliberate decision at the end of twenty twenty five to increase the size of the sales force, to have more sales professionals on the team, to increase the sales and marketing, to really help solidify and drive that change in our selling activities and our business development activities. We've said in the statement that we're expecting those numbers on the administrative costs to flatten out and on the sales and marketing costs to flatten out and or decline, and that may well be a decline relative to selling and revenue. It may well also be a net decline in our sales and marketing costs. We we built the organization.
6:49 We're honing it now. It's a question of making it fit for purpose. So that gets us to that position where we've seen a a reduction in the overall loss first half to first half. And as you mentioned earlier, Rob, that reduction in adjusted EBITDA at a total basis from 400,000 loss to 300,000 loss. But, again, as you highlighted, the reason for this is really important. Reporting our EBITDA before our research development and software maintenance is an important measure for us. It recognizes is the underlying business generating net income that we can use in the rest of the organization.
7:34 Of course, we're gonna have to spend money on software maintenance. Of course, we're gonna have to spend money on research and development. But I think there's been the lack of transparency in previous years before the changes in terms of is the company actually doing what it said it would do, And therefore, distinguishing between the trading in the business, EBITDA before r and d, and the trading in the business after we invest for the future, I think is really important. The balance sheet of this company is really quite simple. There's two or three numbers that are relevant. Obviously, cash. We closed the first half with more cash than we closed at the end of the previous first half, albeit down from the year end. A significant part of that was the borrowing.
8:20 We've gone from a point where there was, just under 1,000,000 at the end of twenty twenty five to 200,000 at the, end of the first half, and that was repaid fully in July. So now the cash flow that's coming from operations allows us to use that cash flow, use those earnings to invest in the business and move it forwards. Here's a critically important one. This is me being a really nerdy bean counter, so I'm sorry, Rob. But when you look at this line for deferred income, this represents the cash that we've received ahead of being able to recognize it as revenue. Unfortunately, if you go back and look at the company's trading history back to 2022, that number fell and fell and fell. And what it actually represents is that's that the new sales orders were not keeping up with revenue generation and were not generating cash within the business.
9:19 When the management change happened in 2024, we saw an improvement in selling in that final quarter twenty four. We saw improvements in selling in 2025. We've seen improvements yet again in 2026, and that shows up in that deferred income line. As an investor, we are. What we want to see is we want to see the deferred income number either increasing or staying static because it actually represents a real movement in the business as a whole. So why don't we move on? What I really wanna do, again, focus on some numbers. Three charts. If you've seen us present before, you've seen these three charts previously. On the left hand side here, we have the order book. You can see that decline when the company's selling actually started to tail off in 2023.
10:11 The big spike was following the acquisition of Winterlight and bringing their order book into the Cambridge COGNITION order book. And then, unfortunately, it starts to slide, and it's led all the way down to the end of twenty twenty four. Since the end of 2024, it's risen. And that for us is a really encouraging sign. In order to be transparent, what we've done is we've shown you the split on a quarter by quarter basis of the new sales orders, and those new sales orders comprise two parts. Absolute new sales orders for new projects and change orders. You can see back in quarter two twenty twenty four, the underlying performance was masked because the change orders were actually such a significant element. We do expect a regular part of change orders to come through this business.
10:57 But as you can see from quarter three twenty twenty four through to the end of twenty six, it's a much more normal base, and therefore, you can measure quarter on quarter, are we actually delivering? We had a little bit of a movement of business from quarter one twenty twenty six into quarter two twenty twenty six, but overall, we've had a reasonably good start to the year. In the outlook section, we've telegraphed a few really important things that the underlying minimum revenue for the year is going to be 10,000,000. We then go on to say, we expect revenue to increase year on year. I know that the equity research analysts at Singer Capital Markets and at, and at Cavendish have both, re upped their forecasts for today. They've adjusted it by the point seven that's moved, but they're both expecting us to deliver an ink net significant increase year on year in revenue.
11:55 So then we turn to the order book. We've told you that we're expecting to have a minimum of 10,000,000 of revenue delivered by the rest of the order book that we've got to go this year. So there's another this is as at the end of August. There's another 3,400,000 to go. But really importantly, we can now start to look into 2027. In 2027, the order book now shows that we should recognize 6,600,000 of revenue without any further selling. If we do the comparison like for like compared to last year, that's up nearly a whole 10%. So we can see that growth. And every time we keep reporting the forward looking order book, I think we're looking at it with real confidence. The order book is now running at a good level, and we'll report again in January following the end of the q four selling. But as I look at these numbers, we're looking forward to a strong end to 2026 and a good start to 2027, and that's really important to us as we move forwards.
12:59 Right. Thanks, Ronald. And so an opportunity to really just step back and make sure that, you know, from our platform strategy perspective, we communicate really where we're focused and where we've refined both our deployment of effort, but also to make sure our ambition is is clear. And so from that perspective, how we envisage this organization is around that one connected science across the whole life cycle of where we deploy and the strategic pillars that we act in. And that is really reflecting the flywheel, which you may have heard us speak about before, and it continues to drive our decision making about where we deploy our investments, but also our efforts and focus in terms of outreach. Those same validated tools that run across the discovery program from drug development all the way into clinic as well.
13:45 We focus down our core area of of product selling when it looks at our core objective of the digital and cognitive voice based assessments with CANTAB and Winterlight. That really is the core of what we are able to bring. It's our strength. It's the evidence base that we continue to build on, and it's what we are recognized as as specialists in the space. But supporting that, we have products that are enablers that help us sell into clinical trials such as the ECOA and the rated training area, which help underpin or access opportunities within that that a co co development might be required. Where we're excited about and where we continue to seek development is around that opportunity with further speech analysis. So this is in addition to our speech based tasks, are defined activities that get analyzed, is in our core. Our speech based analysis really is about doing those longer form activities of being able to support things like central monitoring, but also our applications within health care when we think about ambient scribe as opportunities within that. And that's why one of our investment programs that we've set out this year is around the automation of the voice platform to support that opportunity and growth.
14:55 They are all now built in into our scale platform, CANTAB Connect. Whether we're serving any one of the four markets we address, CANTAB Connect is a platform that allows us to to to serve every single one on the same cost base that sits there. It enables our voice automation through to our self-service, supports our data extraction and data sort of enablement that we have across there. And as we layer that further, it's strengthening. And one of the key developments and piece of work we've done in the first half of this year has been to complete some of the rewrite of that code base. Some of that work should have been completed a number of years earlier, but we've actually set out over the last eighteen months and then completed this year to complete that migration. That now sets us up for greater scalability within the platform as well. So, really, it's built once and it's ready to deploy across all of those four markets.
15:45 And those are academic, clinical trials, health care, and consumer wellness. And we do that by focusing on our strategic pillars, by becoming and securing ourselves as a trusted partner in brain health, recognizing that we're trusted by those who rely on it most, the forty years of repeated independent validation. The impact that we look to make in the real world, so starting with that unmet need, working backwards through our evidence base, and staying focused where Cambridge Commission makes the biggest difference, a technology leader within the brain health space, turning our science, our data, and our IP into that scalable AI ready platform that serves multiple different markets, really creates that operational leverage for greater efficiencies and margin in the future.
16:30 And, of course, underpinning all of that is the team that support that service and delivers that. Under underpinning our delivery and ensuring that we also have really focused investments when we go forward to a stable cost base and then have clear accountability to delivering against those objectives. As I look at the compounding evidence and flywheel that sits across, we sit to serve those four markets I've touched on. And for some of you, this would be a repeat of what it so what you've seen over the course of the last twelve to eighteen months. But just a reminder, for academics, we're supporting them advancing brain health research with our software as a service offering that generates peer reviewed publications and creates key opinion leaders. When it comes to clinical trials, we're supporting pharmaceutical companies, detecting precise treatment effects, and then reducing measurement variability. And that's our end to end service.
17:19 And what we're seeing there is also the expanded therapeutic application in that area, like the screening and recruitment and also the regulatory credibility that we have in that space. We've touched down into health care where we're supporting those clinicians on informed decision making, leveraging our new CANTAB pathway application earlier, more efficient, and more accurate diagnosis in the course and supporting that pathway as well. And then consumer, powering consumer health with those science based cognitive assessments. Again, leveraging our pathway and working to build that longitudinal data through our partnerships, and that drives up large scale real world data and sort of creates that proactive action that drives back into the flywheel. Now to become a trusted partner, it means that we need to make sure that we're focused in the right area. And the question we ask ourselves is, are we moving the needle when it comes to becoming a trusted partner in brain health? And the early signals is we've made significant progress and we continue to make progress in that area. Whether it's in academic research where we've seen the projects increase 5% from the same period year on year, to clinical studies where actually we've seen a 20% increase in the number of studies that we're supporting, up to 71 from a previous term of 60.
18:32 There's a couple of key messages really to take away from this slide. The first one being that question of that reset of commercial and that strategy that we had around tier one, is it working? The answer is yes. And this is demonstrated by the chart on the top left, which is showing the proportion of tier one pharma sales. And from that perspective, you can see how we've moved from 23 through 24 to 25 and now at 54 in '26 where we've had that concerted effort in the first half to sort of deliver that piece. And this reflects also how we look at our pipeline, our forward looking opportunities. That concerted effort in tier one is starting to have effect. And tier one really is those well funded, well positioned by pharmaceutical companies, which are have got a long term r and d program, have multiple different drug development pipelines that's sitting there. But once you get in, you can land and expand across your services as well versus a transactional relationship that sometimes we've experienced with the likes of early phase biotechs.
19:33 We still serve those, and we still look to support those. But by getting into tier one, it really makes that business repeatable and really builds the accountable, and accountability across that. The second message to really take away is around how our product mix is developing. So as you can see on the top right hand side, it's the proportion of sales which are including voice within that. As Cambridge Cognition, we're a recognized brand when it comes to CANTAB and our touch base. And in 2023, we acquired Winterlight Labs, and then we're building building that product and integrating that product. And as you can see as a proportion of sales, that has materially jumped from '23 to where we are today, where over 40% of our sales are inclusive of some kind of voice based product. This might be alongside Cantab or it might be voice standalone, but importantly, what we're seeing is proportion continue to grow and that validation of voice is a new area and a new development and demand that is coming from it. And we're well positioned to serve both our traditional product, Cantab, our voice based product, Winterlight, but also when we combine those solutions together. And that's one of our unique offerings that many others are positioned to actually do at at this point.
20:42 And then finally is the diversity of the order book. The takeaway that we are not concentrated in a single area or in a single phase study that sits in there. When you look at our therapeutic area diversification of the order book, you can see quite an equal balance across multiple different disease areas. And for us, this is a reflection of a lot of the work that goes into demonstrating from academic all the way through to other clinical about how our tools are effective in multiple different disease and therapeutic area applications. And so seeing this reflected within the clinical order book is also a critical signal that we're well positioned that not only when CNS markets grow, we're also positioned to support other areas. And I point out the likes of oncology and cognitive impairment associated with oncology and immunology that subsequently supports us when they grow. It's an expanding targeted addressable market that we have, and we continue to see that progress.
21:37 And then we look at the phases where we've got a good equal balance between that. Between phase one, the shorter term nine to eighteen month window opportunities that the studies that we run to. Phase two, which typically would be between anything from two to three years, and then phase three, which subsequently are three to five year periods that sit across that. And so, again, the real takeaway is we've addressed by targeting the right customers. We're increasing the product mix and not relying on one single product, and we're diverse diversified across multiple different disease areas and also therapeutic areas as well and phase areas. We've also made progress in the trusted partner side when it comes to our health care and our consumer space, and I know we've touched on this over the course of a number of of months.
22:23 The European health care pilot has now moved from being in its pilot phase to its completion and has transitioned into a long term evergreen agreement where we're working with the partner in terms of their geographical expansion as they consider that going forward forward. That's a significant signal about how our product is being used and built into that area, and we're excited about how that progress will run through over the course of the next couple of years and continue to to seek that growth. But importantly, that's only one of many large opportunities that we look to try and achieve when it comes to the health care space. We've seen the geographical expansion with Ivory. We continue to see really good feedback around that adoption within the geographical region. And also importantly, when we look at the collaboration with Aura, the 45,000 participant brain study, where it's now about two months into its study phase at this point. They've achieved their recruitment of 45,000 people, and they are now observing and bringing in the datasets that support it. The important thing about AURA is it's not just the data that they measure that's valuable. It's the insights that they generate off the back of that.
23:25 And so we're excited to be working closely with them and their science team to actually support the generation of seeing how we combine this data and bring and introduce insights that are actionable. You know, if you take, for example, on their platform, they have symptom trackers that are pulling out data around heart rate variability, body temperature. They're not looking at it as a single data point. They're looking how they generate insights. And so we're excited about working with them to bring those kind of insights when it comes to also brain health as well. And so we look forward to providing further updates in due course about how that collaboration is progressing. Now importantly underpinning where we sit is our defense defensible data and our evidence advantage that we sit across. So as we talk about the flywheel across the different markets, this is really how we think about working backwards from extraordinary impact, that second pillar of our strategy.
24:17 We already have a good evidence advantage that we've already built. That broad disease application, that pull through from translational neuroscience from the early stage spanning the broadest range in the industry, and the global scale that we've already been able to demonstrate supported by our cultural neutrality and the language that we support across there. I think this is really reflective of the continued momentum that we see within the number of publications that are being generated. This chart at the bottom left, already this year, we can see that we're seeing a growth of nearly 200 new peer reviewed publications year to date, and that has taken us over the 3,700 publication mark as well. For anybody who's interested, there is a bibliography that is publicly available that you're able to go in and see the different areas that we have research being published on. We're looking forward to being able to share that little bit more in terms of the social media piece that we do to also increase the awareness of the activities that our tests and assessments are being built on.
25:16 But importantly, we don't just rest on what we've already done. We look at how we're building that evidence and accelerate that flywheel even further. They're driven by key collaborations such as IdeaFast, which is looking at endpoints within fatigue. And this opens up a new therapeutic frontier as we've talked about in the broadening application and the increasing opportunities that we have within the clinical trial space. In BioHermes two, the multimodal approach where we're combining both touchscreen, voice alongside blood based biomarkers, This positions the platform as a gold standard reference for when we think about its application within the real world, whether that's health care or whether that's screening into clinical trials. Project Intuition, which has that proprietary dataset that we use for deep analysis, That creates a data moat that is very difficult for competitors to actually replicate from that perspective. You know, millions of data points that we're able to analyze and build new data products already what we have on our existing tests.
26:14 When we think about AI Mind, it's a biomarker grade Alzheimer's risk for those indicators that sit across. This unlocks that early detection and market opportunity. And so by combining these key collaborations, we're creating more evidence that allows us to address more of the market opportunity and then build that flywheel that sits between clinical trials and health care importantly as well. In the new markets, obviously, the work we've been doing with Aura supports consumer evidence layer and the feedback that we get from people using the test. And we've been really encouraged that a lot of these users, 45,000 users, feeding back about how they find the tests engaging and that they want more from that perspective in terms of being able to measure their brain health overall. From the EU health care provider, that reoccurring data flow and the annual recurring revenue that's able to be driven from that market, and the India India ivory opportunity that has been building out proves that multi market scalability that we have within that. So we're encouraged that not only have we built something that is sustainable, but we're now starting to drive the accelerators into that as well.
27:19 And finally, I'm gonna talk a little bit about how we continue to position ourselves and become the brain health technology leader. As we've reflected across our strategy, it's one platform serving core markets. We have integrated digital and voice based assessments that are ready for deployment, and we've got that proven capability to support the scale of delivery such as the Apple and Biogen study and now the AURA study as well. We've completed the upgrade of the platform during the last eighteen months, completing it in the first half of twenty twenty six, and our r and d road map continues to look at how we leverage our data advantage and accelerate the commercialization of those products. Now, fortunately, we had great support as we came in in July this year to raise funds for supporting three key investment programs that we set out. The CE marking and FDA five ten k for CANTAB pathway, our pediatric norms, and Winterlight ASR.
28:14 All of these programs have gone live. They are on track, and we're excited to be able to see the the call out in terms of the progress that we're making. And wonder I whether, Ronald, it's a time to opportunity to reflect on sort of the key passion area that you've been driving alongside the pediatric norms. Yeah. I know the pediatric norms project. Absolutely, a passion project for me, and I'm loving getting involved with the science again. This program, we're looking to recruit 1,200 children, 100 per year group, 50 male, 50 female, all ages from six years old through to 18, generally healthy children. This is the normative dataset. We want to understand how those children perform in our touch screen tests so that we can actually have that underlying data. And the reason that this is important is so that we can use it in a real live fire situation, particularly in health care, but also in the clinical study market. In diseases like attention deficit hyperactivity disorder, it's a disease where or it's in a condition where the subject often takes a very long time to actually get the real help they need in order to be able to move it forward.
29:27 I've seen firsthand the difference when a child is getting the help that they need versus a child not getting the help that they need. It in it interferes with their education. So for me, the pediatric norms project is just a a joy to work on. We're working with some outstanding universities to get this data, and we're hoping to have some really exciting information to move forwards at the end of the year. At that point in time, we wanna get to a point where we can launch a product, and therefore, we're gonna be reaching out to physicians and physician groups to make sure that the product is designed so that they get what they need, but on a universally available product that actually allows the clinician, the physician, the health care worker to be able to really use these in a in a clinical setting and move it forward.
30:20 Thank you. So to wrap up, really, it's a recap of the outlook. We believe that at Cambridge Commission, we are now positioned for sustained profitable growth. We have returned to growth when it comes to accelerating our revenues and the order momentum. We've had progress when it comes to expanding our pipeline with those target customers and having that real focused approach when we go, and we're deepening those relationships as we progress. Importantly, we've underpinned this business with an operational discipline, which will support delivering that margin long term. When it comes to the science, that forty years of evidence is critical. It does set us apart. It does make us unique within that area. We're trusted by thousands of researchers and partners globally, We're looking to make sure that we capitalize on that position, but don't rest on our laurels. How do we continue to accelerate it alongside that?
31:10 When it comes to the market opportunity, we continue to see the growth within the CNS clinical trial market opportunity that we have and our expanding context of use within that. But also when we see and think about the opportunities when we look at health care and consumer that can really support this organization going from that steady growth to something that is exciting that moves us forward in terms of the opportunities we have in front of us. We're seeing the rise of demand for digital endpoints and importantly expanding across those different areas and creating that flywheel effect. We have optionality also when it looks to the likes of the strategic position within Monument Therapeutics, which are encouraged by their progress that they're making today in their phase two study. So the question to take away is sort of why Cambridge Cognition and why invest in Cambridge Cognition.
31:55 We have a strong base to address those opportunities. The platform is set, and we're prime ready to now move forward at pace. A unique positioning which allows us to address those four markets and positions us with that strength. We're differentiated with our offering of both voice and touchscreen assessments on that single platform, again, making sure that we can support partners efficiently deploying our tools and getting value from them from use one. And then ultimately, we've now set ourselves for that next phase of investment to support and accelerate our growth, but with real accountable timelines and outcomes return on investments that can deliver the value for this organization. So we're equally excited to see how this organization moves forward. We're actively driving it, and we're gonna be making sure that we continue to push the boundaries of what we can do within the organization to make it successful for its customers, for its investors, and for its people.
32:47 So thank you. I think we will now move on to any questions that you may have. Perfect. Rob Ronald, if I may just jump back in there. And thank you very much indeed for your presentation this afternoon. Ladies and gentlemen, please do continue to submit your questions just by using the q and a tab that's situated on the right hand corner of your screen. But just while the team take a few moments to review those questions that have been submitted already, just like to remind you that a recording of this presentation along with a copy of the slides and the published q and a can all be accessed via your investor dashboards. Guys, you can see that we have received a number of questions, and thank you to all of those on the call for taking the time to submit their questions. But, guys, at this point, if I may just hand back you to address those where appropriate. And if I pick up from you at the end, that'd be great. Thank you. Thank you. So I'll take the first one. What proportion of current pipeline relates to repeat business from existing customers versus entirely new relationships?
33:38 So I think the key bit to reflect, we have a categorization of how we go through. Part of the challenge of this organization previously was that repeat relationship wasn't being built or developed, and that's something that we've step changed in from that perspective. And so we're looking at material improvement in terms of that repeatability from existing customers. And our aim, we've got a gold standard customer that has that repeatability and and is building up from a proportional value. We're looking to bring more of those customers up that funnel that really makes and reflects how we're actually improving the quality of our engagement. So the proportional piece, I think it's something that I'd love to be able to come back to James and give you a little bit more detail on in terms of the exact piece, but it's materially improved from where we've seen prior years and something that we're focused on building out and continue to in one of those internal metrics to ensure we keep in there. And we've I think in I was gonna add to James' question. He says current pipeline. We use the words pipeline and back and all of it very differently. Pipeline business that we're chasing.
34:40 Whilst we don't look at it and say, are these repeat customers or not? It really is a material proportion of the total pipeline. Obviously, with the business developers out there, we want them to see we want to see them chasing new customers. We also want them to be really engaging with existing customers because our existing customers know we deliver. The delivery against them is exceptional. The the the user standards that we deliver are very, high, and that customer feedback is very high. So that generates when the customer has something that they want to do, We see them again and again. So, yeah, it it's it's quite material. Just picking up on the second question here.
35:25 How much of the 2,600,000 raised is committed to three strategic programs, and what flexibility does that leave to invest in other growth opportunities? So as we said in that penultimate slide, we can identify that about 2,000,000 is tagged to those three projects. We are pretty clear that those are on schedule for time and on schedule for budget. I'm I'm hoping we can bring them in on time and under budget. We don't see there to be a material pressure to bring them in underneath it. And and because of the time period over which that investment is being made, so we're expecting to see that operating cash flow, especially now that the debt's gone, especially now that we can see that return to EBITDA growth before r and d, and that's why we publish it, is there to allow us to have cash to be available to invest in new growth opportunities. I'm delighted that the question is termed and phrased in that way about new opportunities, not just about, oh, cut your costs, generate profit. We're a tech company, and as a tech company, we need to invest to be able to move the business forwards. I think one of the things probably reflects also how we change the operating model internally within the organization, how we look at research and development opportunities and investment opportunities, and and we start with a very defined process.
36:52 It's a PR FAQ for anybody who wishes to take the time, but we start by working out what is the real world impact we're working back from. Can you explain that in just a few paragraphs to anybody external or internal to the business before we even start thinking about the impressive science behind it or the impressive technology behind it? Can we really think about how it is delivering on the impact for either our customers or an end user from that perspective? And that's really allowed us to refine also our r and d prioritization so we can be more effective about leveraging our data and leveraging our technology platform that we already have. And that's something that reflects our focus and making sure that as we use these investments, we're doing sensible, refined investments and really stress testing before we go and press forward with programs that might otherwise not deliver value in the shorter term.
37:43 I'll move on, and thank you, James, for those. I'll move on to what are the key barriers to converted the current health care and consumer wellness pilots into large reoccurring revenue streams. Fantastic question. I'll start with health care. As we've noted, the pilot that has moved now from the first six month pilot into its rollout is an evergreen contract we've we've positioned with them. And so for us, that is ensuring that they are generating value from the assessments. Their clinicians are able to interpret and use those, and that's been part of the pilot feedback program to make sure that we're building the platform and product that allows them to really leverage it. And ultimately, they're able to impact their own business model, whether that's bringing more people into their pipeline to support, or actually making sure people have got a better duty care that comes through.
38:31 And so from that perspective, I think the barriers to that and making sure that we deliver on our, CE marking timelines and our FDA timelines to make sure that we can support that. These pilots we've signed are not dependent on those milestones, but it's important that when we move from inbound to outbound that that position takes one of the conversations out because as we position it as an informational product at this time, it also creates a barrier when it comes to the CE marking for Yep. New entrants or competitors. So for us, it's really making sure that those tools are being utilized and the interpretation is being utilized to support better informed decisions and better clinical efficiency. And so far, we're encouraged by the progress that's made. When it comes to consumer, it reflects back on a little bit that we covered in the presentation that it's moving from just being a piece of data that is available to someone to actually something that is combined with their own datasets and their insights to generate something that is potentially interventional.
39:28 So how can I actually improve my brain health? I may not be impaired. I may be a healthy individual, but I wanna continue to improve my brain health overall. How do I generate insights whether that's related to doing more vigorous exercise, which actually we had a study released just recently around how doing high intensity, high intensity vigorous exercise actually has an improved executive function impact, but not actually anything within memory. So there are these interventions, e fingers being another piece that is a large study, reflects on that 40 of dementia cases that can be actually supported with interventional steps. And so we believe that that's really our our working case, and so we're advantaged by working alongside Aura to be able to provide those insights and generate them. I think that will also then address some of those, any blockers or any challenges to them really turning into a recurring revenue stream. For us, the platform, the technology, the tests are tried, tested, proven.
40:26 For us, it's really about how we support our partners being able to make sure they can leverage the full value of what we believe is fantastic science. Yeah. For me, I think it's it's the learning that we're doing. Yes. We're supporting our our partners in both health care and consumer health, Aura. But what we're doing in at the moment is really learning about what their needs are so that we can really apply that when we go full outbound in terms of marketing. The the conversations with those organizations started late last year. They've contracted this year. Now that we're getting that learning coming through, we set out our ambition back in May 2025 that we wanted to be in this space, and it's becoming an increasingly important view as to how we move this forwards. So it's about taking that learning and really deploying it in the real world.
41:20 We want to understand. Every time I watch your presentation, I'm more impressed by the significance of what you offer, but curious to why the revenue figures are so modest. Could you give some indications as to the size of the total addressable market that you now believe you're looking to address these? Thank you very much, Chris. Fantastic question. It's actually I'll probably stop back and and reflect on the slide that we present where we say sales to orders to revenue flow. Because the important thing about our current model at the moment when we think about academic and the clinical trials market is the sales to revenue conversion takes a long time. It's a long pull. Thinking about the different phases and the timelines, you sign a study upfront that might generate cash, but then subsequently, you've got a five year period where that revenue will be trailing off as you you deliver.
42:05 And it's why continuing a modest and and progressive sort of sales cycle and sales targets across will naturally grow the revenue position of the organization and will flow through, and you've gotta keep it consistent. So part of this has been catching up from where we've had those lower sales years in terms of the twenty threes and the twenty fours, catching back up to where our natural cycle would be, and then that would support accelerated sales motions and and revenue that converts from that perspective. The sorry. No. I was gonna say that's absolutely right, and I think that move into particularly health care is where that total addressable market. We presented information to the board during a strategy session a month or so ago, and and I'm just not gonna talk about those numbers in public because they make me smile.
42:52 The challenge is to go and access those markets. Those those those addressable markets are potentially in health care enormous. The challenge that we've now got is to get the product right, to get the business development for those products right, to find the right customers. We've got amazing Sentinel customers in the form of the European Healthcare Organization and Inora. We couldn't be happier to be working with them because they give us direct feedback, building that feedback, and then delivering the right product to the market. So we would hope that we'll cut multiple deals during 2027, and those deals will then start to mature in '27 and '28 and '29 and beyond.
43:37 And we were challenged by a fairly significant shareholder to say, should we be expecting to see really material revenues out of, health care and consumer by 2030? And we said, I'll eat my hat if we don't because it really is where we can see this enormous growth coming forward. And once we crack those health care markets, we'll have use in the clinic, and that use in the clinic will actually have a positive feedback effect into the clinical study piece. Just moving on to the next. What guidance can you give to the timeline for getting the FDA and c approvals? How will life change when you get these approvals? Another great question. Thank you. The c marking as we set out with our investment program, we're looking at q one twenty twenty seven in terms of those those programs of work. We're actively engaged on that and moving that forward. One of the advantages is we are already an ISO thirteen four eight five accredited organization.
44:34 We already have experience in CE marking and also FDA approvals from that perspective. And so it's about moving through that in a timely workmanage fashion to be able to deliver the the dossier of work that sits across. Once completing the CE marking piece, we then will complete the FDA piece, which will move through into the back end of 2027. The question around how will life change for us is important that we, at the moment, all of the deals and engagement that we've had to date has been customers coming to us, recognizing us as leaders in this space. And so whether it's Aura all the way through to the pan European health care provider, they have come to us having already used our tools or been in an academic space to leverage our tools and know that the trust is in in science. So for us, the excitement is the opportunity to be able to move from that inbound period to then actually being able to actively and go out and drive our marketing engine and really create commercialization.
45:29 And that's what the CE and the FDA market will allow us to do really in full earnest, and that's how life will change for us. And it's something that I'm desperately excited as Absolutely. Leader of the business to to move towards because having seen so much inbound, being able to move to the outbound model will certainly give us the encouragement. And and we're talking with, you know, fantastic names that also give that feedback about where we are as a business. So that's that's how I really see it being able to change. It's allowing us to accelerate into the the revenue models and the reoccurring revenue models for that 2028 and beyond. Perfect. Rob, Ronald, if I may just jump back in there. And thank you very much indeed for addressing all of those questions that came in from investors this afternoon. Of course, if there are any further questions that do come through, we'll make these available to you immediately after the presentation has ended. But Rob, perhaps before really now, just looking to redirect those on the call to provide you with their feedback, which I know is particularly important to yourself and the company. I could please just ask you for a few closing comments just to wrap up with, that'd be great.
46:27 Yeah. Thank you. And first of all, I wanna appreciate and and and recognize and acknowledge the the time you take to sit with us and go through these these presentations. One thing we've tried to be make sure we've done over the last twelve, eighteen months is to make sure we create that transparency, that consistency. So, hopefully, you've seen through our presentations some reoccurring slides so you're able to measure and see period on period how we're improving from that perspective and be honest where things aren't working and drive the the business. We're deeply excited about the opportunity this organization has got. We've stabilized it. We've underpinned the piece that already sits to our existing markets with academic and clinical trials, and we're now optimizing those markets. But the real opportunity is how we accelerate going into the health care and the consumer side and really bringing that flywheel to generate the value, create the long term value for the organization, the revenues, and the profitability that under sit it. And I think we are primed with a unique offering with a platform that's ready to go and deliver those opportunities as well. And I'm really excited about what that next twelve to eighteen months can really do to bring the real true value to this organization out into the public and be recognized for that true neuroscience technology leader that we believe we are in this space.
47:42 And I say thank you for your time. If you do have any questions, please also feel free to reach out to us to press at camcog dot com. We'd always be willing to to, share any feedback or any questions or address those as well. We love that engagement. And if you ever are interested coming to the site to meet some of our fantastic team as well, that's also welcome as well. We love having people come in and us telling them the story about where we are and where we believe we're gonna be in the future. That's great. Rob, Ronald, thank you once again for updating investors, this afternoon. Could I please ask investors not to close this session as you will now be automatically redirected for the opportunity to provide your feedback? On behalf of the management team, we'd like to thank you for attending today's presentation. That now concludes today's session. So good evening to you all.
Follow Cambridge Cognition Holdings PLC into a list and get an email when it puts out news.
Chief Executive Officer at CAMBRIDGE COGNITION HOLDINGS PLC
Chief Financial Officer and Head of Corporate Development at CAMBRIDGE COGNITION HOLDINGS PLC